Compass Therapeutics, Inc. (CMPX)
0.6882
+0.01
(+1.43%)
USD |
NASDAQ |
Nov 20, 16:00
0.6834
0.00 (0.00%)
After-Hours: 20:00
Compass Therapeutics Research and Development Expense (TTM) : 68.60M for Sept. 30, 2026
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2026 | 68.60M |
| June 30, 2026 | 59.39M |
| March 31, 2026 | 56.15M |
| December 31, 2025 | 55.69M |
| September 30, 2025 | 54.93M |
| June 30, 2025 | 50.59M |
| March 31, 2025 | 45.30M |
| December 31, 2024 | 41.75M |
| September 30, 2024 | 41.12M |
| June 30, 2024 | 41.32M |
| March 31, 2024 | 40.34M |
| December 31, 2023 | 37.42M |
| September 30, 2023 | 34.89M |
| June 30, 2023 | 35.81M |
| Date | Value |
|---|---|
| March 31, 2023 | 31.41M |
| December 31, 2022 | 29.21M |
| September 30, 2022 | 28.93M |
| June 30, 2022 | 22.50M |
| March 31, 2022 | 19.76M |
| December 31, 2021 | 20.21M |
| September 30, 2021 | 15.17M |
| June 30, 2021 | 15.68M |
| March 31, 2021 | 15.76M |
| December 31, 2020 | 14.63M |
| September 30, 2020 | 13.53M |
| June 30, 2020 | 15.84M |
| March 31, 2020 | 18.24M |
| December 31, 2019 | 21.91M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Viking Therapeutics, Inc. | 586.17M |
| Capricor Therapeutics, Inc. | 107.50M |
| Ardelyx, Inc. | 91.28M |
| Biomea Fusion, Inc. | 34.91M |
| ARS Pharmaceuticals, Inc. | 30.74M |